Prognostic significance of p16INK4a expression and integrated human papillomavirus oncogen transcripts in dysplastic lesions of the uterine cervix

CME Journal of Gynecologic Oncology

Volumn 8, Issue 3, 2003, Pages 227-232

  Von Knebel Doeberitz, Magnus ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cervical cancer; Human papillomavirus; P16INK4a expression; Prognostic significance

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN E6; PROTEIN E7; PROTEIN P16; PROTEIN P16INK4A; UNCLASSIFIED DRUG;

CANCER SCREENING; CARCINOGENESIS; CYTOLOGY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PAPANICOLAOU TEST; PROGNOSIS; REVIEW; UTERINE CERVIX DYSPLASIA; WART VIRUS;

EID: 1442301787     PISSN: 12199087     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Klaes R, Friedrich T, Spitkovsky D, Ridder R, Rudy W, Petry U, et al. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92:276-284.
2. Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, et al. Detection of high-risk cervical intraepithelial neoplasia and cervical cancer by amplification of transcripts derived from integrated papillomavirus oncogenes. Cancer Res 1999; 59:6132-6136.
3. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999; 80:827-841.
4. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990 [published erratum appears in Int J Cancer 1999; 10:83(6):870-873]. Int J Cancer 1999; 83:18-29.
5. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990 [published erratum appears in Int J Cancer 1999; 10:83(6):870-873]. Int J Cancer 1999; 83:18-29.
6. Papanicolaou GN, Traut HF. The diagnostic value of vaginal smears in carcinoma of the uterus. 1941 [classical article]. Arch Pathol Lab Med 1997; 121:211-224.
7. Segnan N. Cervical cancer screening. Human benefits and human costs in the evaluation of screening programmes. Eur J Cancer 1994; 30A:873-875.
8. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA 1994; 271:1866-1869.
9. McCluggage WG, Walsh MY, Thornton CM, Hamilton PW, Date A, Caughley LM, et al. Inter- and intra-observer variation in the histopathological reporting of cervical squamous intraepithelial lesions using a modified Bethesda grading system. Br J Obstet Gynaecol 1998; 105:206-210.
10. Ismail SM, Colclough AB, Dinnen JS, Eakins D, Evans DM, Gradwell E, et al. Reporting cervical intra-epithelial neoplasia (CIN): intra- and interpathologist variation and factors associated with disagreement. Histopathology 1990; 16:371-376.
11. Sasieni PD, Cuzick J, Lynch-Farmery E. Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group. Br J Cancer 1996; 73:1001-1005.
12. Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500-1505.
13. Grenko RT, Abendroth CS, Frauenhoffer EE, Ruggiero FM, Zaino RJ. Variance in the interpretation of cervical biopsy specimens obtained for atypical squamous cells of undetermined significance. Am J Clin Pathol 2000; 114: 735-740.
14. Woodhouse SL, Stastny JF, Styer PE, Kennedy M, Praestgaard AH, et al. Interobserver variability in subclassification of squamous intraepithelial lesions: Results of the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med 1999; 123:1079-1084.
15. Jones MH, Singer A, Jenkins D. The mildly abnormal cervical smear: patient anxiety and choice of management. J R Soc Med 1996; 89:257-260.
16. Sherlaw-Johnson C, Gallivan S, Jenkins D, Jones MH. Cytological screening and management of abnormalities in prevention of cervical cancer: an overview with stochastic modelling. J Clin Pathol 1994; 47:430-435.
17. Zur HH. Papillomaviruses in human cancers. Proc Assoc Am Physicians 1999; 111:581-587.
18. Stoler MH. Advances in cervical screening technology. Mod Pathol 2000; 13: 275-284.
19. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, el al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet, 357: 1831-1836, 2001.
20. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998; 338:423-428.
21. Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12:186-192.
22. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix [see comments]. J Natl Cancer Inst 1999; 91:252-258.
23. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
24. Lazo PA. The molecular genetics of cervical carcinoma. Br J Cancer 1999; 80: 2008-2018.
25. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001; 93:293-299.
26. Black WC. Overdiagnosis: An underrecognized cause of confusion and harm in cancer screening. J Natl Cancer Inst 2000; 92:1280-1282.
27. Zur HH. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000; 92:690-698.
28. White AE, Livanos EM, Tisty TD. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev 1994; 8:666-677.
29. Chu TY, Shen CY, Lee HS, Liu HS. Monoclonality and surface lesion-specific microsatellite alterations in premalignant and malignant neoplasia of uterine cervix: a local field effect of genomic instability and clonal evolution. Genes Chromosomes. Cancer 1999; 24:127-134.
30. Galloway DA, McDougall JK. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 1996; 7:309-315.
31. Duensing S, Lee LY, Duensing A, Basile J, Piboonniyom S, Gonzalez S, et al. The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle. Proc Natl Acad Sci USA 2000; 97:10002-10007.
32. Duensing S, Munger K. Centrosome abnormalities, genomic instability and carcinogenic progression. Biochim Biophys Acta 2001; 1471:M81-M88.
33. Duensing S, Duensing A, Crum CP, Munger K. Human papillomavirus type 16 E7 oncoprotein-induced abnormal centrosome synthesis is an early event in the evolving malignant phenotype. Cancer Res 2001; 61:2356-2360.
34. Von Knebel DM, Oltersdorf T, Schwarz E, Gissmann L. Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 1988; 48:3780-3786.
35. Von Knebel DM, Rittmuller C, Zur HH, Durst M. Inhibition of tumorigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA [letter]. Int J Cancer 1992; 51:831-834.
36. Von Knebel DM, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994; 68: 2811-2821.
37. Ylitalo N, Sorensen P, Josefsson AM, Magnusson PK, Andersen PK, Ponten J, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2194-2198.
38. Josefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen P, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000; 355:2189-2193.
39. Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153:1741-1748.
40. Durst M, Glitz D, Schneider A, Zur HH. Human papillomavirus type 16 (HPV 16) gene expression and DNA replication in cervical neoplasia: analysis by in situ hybridization. Virology 1992; 189:132-140.
41. Durst M, Bosch FX, Glitz D, Schneider A, Zur HH. Inverse relationship between human papillomavirus (HPV) type 16 early gene expression and cell differentiation in nude mouse epithelial cysts and tumors induced by HPV positive human cell lines. J Virol 1991; 65:796-804.
42. Stoler MH, Rhodes CR, Whitbeck A, Wolinsky SM, Chow LT, Broker TR. Human papillomavirus type 16 and 18 gene expression in cervical neoplasias. Hum Pathol 1992; 23:117-128.
43. Galloway DA, McDougall JK. The disruption of cell cycle checkpoints by papillomavirus oncoproteins contributes to anogenital neoplasia. Semin Cancer Biol 1996; 7:309-315.
44. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 1996; 93:4350-4354.
45. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol 1991; 65:606-612.
46. Von Knebel DM, Bauknecht T, Bartsch D, Zur HH. Influence of chromosomal integration on glucocorticoid-regulated transcription of growth-stimulating papillomavirus genes E6 and E7 in cervical carcinoma cells. Proc Natl Acad Sci USA 1991; 88:1411-1415.
47. Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol 1995; 69:2989-2997.
48. Jeon S, Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 1995; 92:1654-1658.